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Abstract
Background—Human pluripotent stem cells (hPSCs) hold great promise for treating ischemic
heart disease. However, current protocols for differentiating hPSCs either result in low yields or
require expensive cytokines.
Methods—Here we developed a novel two dimensional (2D) stepwise differentiation system that
generates a high yield of cardiomyocytes (CMs) from hPSCs without using special cytokines.
Initially, undifferentiated hPSCs were transferred onto Matrigel-coated plates without forming
embryoid bodies (EBs) for a few days and were cultured in bFGF-depleted human embryonic
stem cells (hESCs) medium. When linear cell aggregation appeared in the margins of the hPSC
colonies, the medium was changed to DMEM supplemented with 10% fetal bovine serum (FBS).
Thereafter when cell clusters became visible, the medium was changed to DMEM with 20% FBS.
Results and Conclusions—At about two weeks of culture, contracting clusters began to
appear and the number of contracting clusters continuously increased, reaching approximately
70% of all clusters. These clusters were dissociated by two-step enzyme treatment to monolayered
CMs, of which ~90% showed CM phenotypes confirmed by an α –myosin heavy chain reporter
system. Electrophysiologic studies demonstrated that the hPSC-derived CMs showed three major
CM action potential types with 61 to 78% having a ventricular-CM phenotype. This differentiation
system showed a clear spatiotemporal role of the surrounding endodermal cells for differentiation
of mesodermal cell clusters into CMs. In conclusion, this system provides a novel platform to
generate CMs from hPSCs at high yield without using cytokines and to study the development of
hPSCs into CMs.
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Introduction
Heart failure is the leading cause of death worldwide. Current therapies including surgical
and pharmacological interventions are only capable of delaying the progression of this
devastating disease [1]. Since human CMs have very little or no regenerative capacity, the
damage to CMs resulting from various heart diseases is irreversible and frequently leads to
heart failure [2]. Recent discovery of pluripotent stem cells (PSCs) such as embryonic stem
cells (ESCs) and induced pluripotent stem cells (iPSCs) has allowed the use of PSCs for cell
therapy [3]. hESCs proliferate unlimitedly and differentiate into cells of all three germ layers
[4]. hESC-derived CMs (hESC-CMs) hold similar structural and functional properties to
native CMs and showed a potential to integrate into the recipient heart when transplanted in
vivo [5–8]. Thus, hESCs can be an appropriate source for cardiac cell-based therapy.
However, use of hESCs for therapy has been limited due to ethical controversy. Recent
discovery of hiPSCs opened a new avenue for using similar PSCs while avoiding ethical
controversy and immunological mismatches associated with hESCs. hiPSCs have been
generated from various human somatic cells by introducing pluripotency factors through
viral and non-viral delivery techniques, and possess almost identical cell biologic
characteristics to hESCs [9–13]. Several independent groups have successfully generated
CMs from human PSCs [14–19]. These differentiated CMs displayed many of the properties
of primary CMs including the appearance of spontaneous contraction, expression of CM-
specific genes and proteins, and electrophysiological characteristics including the expected
responses to known pharmacological agents [20–22]. The most common method to induce
CM differentiation is EB-mediated differentiation. EBs are round multi-cellular three
dimensional aggregates which are formed via suspension culture and consist of cells
representing all three germ layers [23, 24]. Typically, a part of the aggregated EBs mature
into spontaneously contracting CM-like cells during culture [16, 18]. While the results of
EB-mediated CM differentiation have been fairly successful, the method has several
limitations. Conventional methods to form EBs yield significant variations in the size and
cell number of EBs, and human EBs (hEBs) have different differentiation capabilities
dependent on the size [25]. hEBs do not induce specific distribution patterns of three germ
layers, and their descendent lineages are heterogeneous, resulting in variations in
cardiomyogenic differentiation [23, 24]. Moreover, EBs are often fused together to form
large aggregates causing extensive cell death [23]. Finally, the process for forming EBs is
labor-intensive and therefore is considered an obstacle for mass production for therapeutic
use.
Another approach for inducing CM differentiation is to co-culture PSCs with a mouse
visceral endoderm-like cell line, END-2 [6]. It has been demonstrated that direct cell-cell
interactions or secreted factors from the END-2 cells are capable of stimulating CM
differentiation in vitro [26]. Although this system is reliable for generating CMs, it results in
a relatively heterogeneous and undefined mixture of other cell types, which may require
another step for isolating a pure population of CMs [14]. Recently, a high-density monolayer
model has been introduced for CM differentiation [15, 17]. In this protocol, PSCs are
cultured in a feeder-free system for cell expansion and undergo cardiomyogenic
differentiation by the addition of serum-free medium supplemented with several
developmental-stage-specific cytokines such as BMP4, Activin A and VEGF [15, 17].
However, this system requires expensive cytokines and yielded ~30% CMs. Common
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problems for the above methods are the difficulties in enrichment of CMs, as these systems
result in heterogeneous cell mixtures. To purify CMs, Percoll density gradient or antibody-
based cell isolation for KDR have been developed; however, the yield was variable and
KDR+ cell sorting resulted in cardiac progenitor cells but not pure CMs [3, 15, 27].
In the present study, we developed a novel 2D, directed differentiation system which can
generate a high yield of differentiated CMs without using cytokines. The identity of
differentiated CMs was verified by immunocytochemistry, gene expression studies,
electrophysiology, and a CM-specific viral reporter system. Of note, we discovered the
significant contribution of endodermal lineage cells to the differentiation and maturation of
CMs as seen in developmental cardiomyogenesis. This differentiation system can serve as
an important platform to investigate cardiomyogenesis.
1. Materials and methods
The authors of this manuscript have certified that they comply with the Principles of Ethical
Publishing in the International Journal of Cardiology [28].
1.1. hPSC culture
hiPSC lines were generated by the lentivirally-mediated four transcription factors (OCT4,
SOX2, c-MYC and KLF4) as previously described [29]. In this study, we used a hiPSC line
derived from human dermal fibroblasts (BJ1) and a hESC line H1 [4, 29]. Briefly,
undifferentiated hPSCs were grown on mitotically inactivated STO cells (ATCC, Manassas,
VA) in DMEM/F12 (50:50; Gibco BRL, Gaithersberg, MD) supplemented with 20% (vol/
vol) serum replacement (Gibco) and basic hESC medium, including 1 mM L-glutamine
(Gibco), 1% nonessential amino acids (Gibco), 100 mM mercaptoethanol (Gibco), and 4 ng/
ml basic fibroblast growth factor (bFGF; Sigma Aldrich Inc., St. Louis, MO) [30]. The
medium was changed every 24 hours, and hPSCs were transferred to new feeder cells every
5 to 7 days using dissecting pipettes.
1.2. Differentiation of hPSCs into CMs using a 2D system
For hPSC-CMs differentiation by the 2D system, cultured hPSCs were plated at 3 × 105
cells per well on Matrigel (BD Biosciences, Bedford, MA)-coated 6-well plates (Nunc,
Roskilde, Denmark) without feeder cells as previously described [31]. Attached hPSCs were
expanded in hESC media for 4 days (Stage 1), and then cultured in hESC media without
bFGF for three days (Stage 2). Next, the aggregated cells were transferred into DMEM
containing 10% FBS (HyClone, Logan, UT) and cultured for 7 days to form clusters (Stage
3). Finally, FBS was increased to 20% and the clusters were more clearly demarked, with
some clusters showing contraction within 7 days (Stage 4). All culture medium was changed
every 24 hours.
1.3. Isolation of CMs using two step enzyme treatments
To isolate purified CMs from contracting clusters at stage 4, we used a two-step enzyme
treatment. First, peripheral cells surrounding contracting clusters were removed by 0.05%
trypsin-EDTA treatment (Invitrogen, Grand Island, NY). The remaining contracting clusters
were detached by 0.25% trypsin-EDTA (Fig. 1C). The isolated contracting clusters were
replated onto 0.1% gelatin-coated plates and cultured with DMEM containing 2% FBS [18].
Under these conditions, the contracting clusters formed a monolayer-like structure (Fig. 1E,
left panel). We further digested these compact clusters by incubation with 0.25% trypsin-
EDTA and made true monolayered cell sheets by culturing the cells on 0.1% gelatin
(Sigma)-coated plates. Single cells and small clusters composed of less than 10 cells
continued to beat even after digestion (supplemental online Movie 4).
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1.4. Real-time RT-PCR (qRT-PCR)
To analyze gene expression patterns at each stage (Fig. 1A, cell populations indicated by
white arrows), we performed real-time RT-PCR (qRT-PCR) as described previously [32].
Total RNA was isolated using TRIzol Reagent (Molecular Research Center, OH) according
to the manufacturer’s instructions. Two μg of RNA was used for cDNA synthesis with
SuperScript II reverse transcriptase according to the manufacturer’s instructions
(Invitrogen). Real time PCR was performed with SYBER Green PCR master mix using
7500 Fast RT-PCR System. GAPDH cDNA was used as an internal control. Primer
sequences are listed in Supplemental online Table 1.
1.5. Construction of α-MHC viral reporter system
We utilized lentiviral vectors (courtesy of Dr. Miyoshi) as backbones to construct a human
α-myosin heavy chain (MHC) viral reporter system. (http://www.brc.riken.go.jp/lab/cfm/
Subteam_for_Manipulation_of_Cell_Fate/Plasmid_List.html). CSII-EF-Venus was
incubated with AgeI to delete its EF-1 promoter. The digested vector was self-ligated with
T4 DNA ligase. CSII-ΔEF-Venus was double-digested by BamHI and XbaI, then ligated
with the fragment of IRES2-BSD containing the same double-digestion sites from CSII-
CMV-MCS-IRES2-BSD. To construct CSII-ΔEF-GFP-IRES2-BSD, eGFP was amplified by
PCR using the following primers:
5′ ATATATGCGGCCGCAAGGATCCCCGGGTACCGGTCGCCACC, 5′
ATATATAGATCTTTACTTGTACAGCTCGTCCATG,
with pEGFP-N1 as a template, and were double-digested by NotI and BglII. The eGFP
fragment was pasted into the sites of NotI and BamHI in CSII-ΔEF- IRES2-BSD. The
fragment of human α-MHC promoter (3068 bp) was amplified by PCR using the following
primers
5′ ATATATGCGGCCGCCCAGACAGAGCTCCCTCAAACCA, 5′
ATATATGGATCCTCCTCAAAGCTCCAGTTCCTTTAT,
with human genomic DNA as a template. These synthetic DNAs were double-digested by
NotI and BamHI and ligated with NotI/BamHI-digested CSII-ΔEF-GFP-IRES2-BSD for the
construction of α-MHC-GFP-IRES2-BSD. Lentiviral particles were produced in 293T cells
using an α-MHC reporter with packaging plasmids pMDL-gp-RRE and pCMV-VSV-G-
RSV-Rev. The sequences of the constructs were verified by DNA sequencing.
1.6. Immunocytochemistry
Immunocytochemistry was performed as described previously [33]. Briefly, cells were fixed
with 4% paraformaldehyde (PFA) for 20 minutes and permeabilized with 0.1% Triton
X-100 in phosphate buffered saline (PBS, Sigma) for 5 minutes. After treatment with 5%
normal goat serum for 30 minutes, the cells were incubated for 12 hours at 4°C with
antibodies against the following proteins: a pluripotency marker OCT4 (Santa Cruz
Biotechnology Inc., Santa Cruz, CA), mesodermal lineage markers Brachyury (Abcam Inc.,
Cambridge, MA) and HAND1 (Santa Cruz Biotechnology), cardiac-lineage markers NKX2–
5, cardiac troponin T (cTnT), α-MHC (Abcam), connexin 43, GATA4 (BD Bioscience),
MEF2C (Abgent Inc, San Diego, CA), β-MHC (Millipore, Billerica, MA), MLC2a, and
MLC2v (Synaptic Systems, Goettingen, Germany), and endodermal lineage markers
FOXA2 (Abcam) and AFP (Abcam). Cells were washed three times with PBS and then
incubated with rhodamine or FITC-conjugated secondary antibodies (Molecular Probes Inc.,
Eugene, OR) for 1 hour. DAPI counterstaining was performed. All images were analyzed
with an LSM 510 META confocal microscope (Carl Zeiss Inc., Oberkochen, Germany).
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1.7. Electrophysiologic study
The intracellular AP was recorded as described previously with slight modification [5]. The
beating cells isolated from contracting clusters by two step enzyme treatment at stage 4 were
transferred and cultured on 0.1% gelatin-coated glass bottom microwell dishes for 5 to 7
days. For intracellular recording, the 35-mm dishes were mounted on an inverted
microscope (Olympus IX71, Japan) and heated by a heating/cooling bath temperature
controller (DTC-200, Dagan Corporation, Minneapolis, MN). The contracting clusters were
perfused with Tyrode’s solution containing (mmol/L) 140 NaCl, 5.4 KC1, 1 MgCl2, 10
HEPES, 10 glucose, 1.8 CaCl2, pH 7.4 with NAOH 37°C. Glass microelectrodes were
fabricated from borosilicate glass (PG52151-4, World Precision Instruments, Inc., Sarasota,
FL) and pulled on a P-87 Flaming/Brown puller (Sutter Instrument Company, Novato, CA).
The tip resistance of the microelectrode was 40–80 M when filled with a 3 mol/L KCl
solution. Intracellular recordings of membrane potential were performed using an EPC 7
amplifier (List Medical, Darmstadt, Germany) in current clamp mode at 37 ± 0.5°C. The
junction potential between the microelectrode solution and the bath solution was adjusted to
zero and the microelectrodes’ capacitance was compensated. Spontaneously contracting cell
clusters were impaled with the sharp microelectrodes and the spontaneous APs were filtered
at 10 kHz and digitized on a computer at 10 kHz. APs were analyzed using Origin 6.0
software (Microcal Inc, Northampton, MA).
1.8. Induction of myocardial infarction and cell transplantation
All protocols for animal experiments were approved by the Institutional Animal Care and
Use Committee of Emory University and conformed to the National Institutes of Health
Guide for the Care and Use of Laboratory Animals. Myocardial infarction (MI) and cell
transplantation was performed in athymic male nude rats (Rh-rnu/rnu, 200–250g, Harlan,
IN) as previously described by our group (n = 7) [33]. Briefly, MI was induced by ligation
of the left coronary artery. Immediately after ligation, the enriched hPSC-CMs were injected
into the border zone surrounding the infarcted region (1×106 cells in 100 μl PBS). Before
cell transplantation, the cells were labeled with a red fluorescent dye, CM-DiI (Molecular
Probes, NY) for the detection of injected cells in histologic sections.
1. 9. Histological analysis
Rats were euthanized after 7 weeks and the heart tissues were retrieved. Specimens were
embedded in OCT compound (TISSUE-TEK® 4583, Sakura Finetek USA Inc., CA), frozen,
and cut into 8–12 μ thick sections at −20°C. For examining fibrosis and tumor formation,
specimens were stained with Masson’s trichrome. For examining engraftment, the tissue
sections were stained with a primary antibody against TnT (Abcam Inc., Cambridge, MA) or
Connexin 43 (BD Biosciences, Bedford, MA) followed by FITC-conjugated secondary
antibodies (Molecular Probes). All images of were acquired using a confocal microscope
(Carl Zeiss Inc., Oberkochen, Germany).
1.10. Statistical analysis
All experiments were performed at least 3 times. Quantitative data are expressed as the
mean ± standard derivation (SD). Student’s paired t-test or one-way ANOVA was
performed to analyze statistical significance. Prespecified comparisons between groups were
made where appropriate with post hoc testing using Tukey’s method (SPSS, version 17). A
P value< 0.05 was considered statistically significant.
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2. Results
2.1. Cardiomyogenic differentiation of hPSCs by a FBS-induced 2D-directed differentiation
system
In this study, we have developed a new FBS-induced 2D-directed CM differentiation system
to obtain highly purified CMs from hPSCs. Undifferentiated hPSCs cultured on STO feeder
cells (H1 or BJ1, supplemental online Fig. 1) were transferred to Matrigel-coated 6 well
plates (Fig. 1A, Day -5) and cultured in hESC medium for 4 days. Colonies of
undifferentiated hPSCs were expanded (Fig. 1A, white arrows in Stage 1). The cells were
then cultured in bFGF-depleted hESC medium for 3 days and became aggregated at the
interfaces of growing hPSC colonies (Fig. 1A, white arrows in Stage 2). The aggregated
cells were cultured under DMEM/10%FBS for another 7 days and grew further and formed
round clusters (Fig. 1A, white arrows in Stage 3). Next, FBS was increased to 20% to
enhance cardiomyogenic differentiation, and the first contracting clusters appeared after ~7
days (Fig. 1A, white arrow in Stage 4). A majority of the clusters contracted over the next 4
to 5 days (supplemental online Movie 1). When 20% FBS was used instead of 10% FBS at
stage 3, more floating cells were observed (white arrows in supplemental online Fig. 2A).
Most floating cells were apoptotic based on trypan blue staining (supplemental online Fig.
2B). In contrast, continuous use of 10% FBS throughout stage 4 led to a lower number of
contracting clusters (data not shown). Based on these results, 10% FBS was used to decrease
apoptotic cells at stage 3 and switched to 20% FBS to enhance contracting cluster formation
at stage 4.
2.2. Enrichment of CMs from contracting clusters
Cardiomyocytes were enriched from contracting clusters by using a two-step enzyme
treatment. First, peripheral cells in contracting clusters (Fig. 1B) were removed by 0.05%
trypsin-EDTA treatment (Fig. 1C). Subsequently, the remaining compact cells in the center
of the clusters (Fig. 1C) were treated with 0.25% trypsin-EDTA treatment (Fig. 1D, left
panel). Such dissociated clusters remained contractile while expressing cTnT and α-MHC
(Fig. 1D and supplemental online Movie 2). These clusters were replated onto 0.1% gelatin-
coated dishes and cultured under 2% FBS [15]. These dissociated clusters formed a
monolayer (Fig. 1E, left panel) while contracting, and expressed α-MHC (Fig. 1E and
supplemental online Movie 3). Next, these clusters were digested into finer pieces by
incubating with 0.25% trypsin-EDTA, and cultured on 0.1% gelatin-coated plates. Single
cells and small clusters composed of less than ten cells were observed (Fig. 1F and
supplemental online Movie 4). Most of the contracting cells expressed CM specific markers,
such as α-MHC, cTNT, NKX2–5, CONNEXIN 43, β-MHC, GATA4 and MEF2C (Fig. 1F).
Next, we determined the purification efficiency measured by the proportion of CMs stained
positive for GATA4, NKX2–5, α-MHC or cTNT divided by DAPI-positive cells and found
that more than 90% of the monolayered cells were cardiomyogenically differentiated cells
(Fig. 1G). This new 2D-directed CM differentiation and enrichment system yields highly
purified CMs from hPSCs.
2.3. Confirmation of enriched CMs using a lentiviral α-MHC reporter system
Next, we sought to confirm the efficiency of CM generation using a viral promoter system.
To do this, we constructed α-MHC reporter system using a lentiviral vector system (Fig.
2A). Viral particles expressing α-MHC-driven GFP were applied twice during stage 2 and 3
(Fig. 2B). GFP-expressing contractile clusters appeared at stage 4 (Fig. 2C and supplemental
online Movie 5). We took advantage of antibiotic resistance for CM selection, because this
reporter contains a Blasticidin resistance gene driven by an IRES sequence, whose
expression is dependent on GFP expression (Fig. 2A). Treatment with Blasticidin could
eliminate non-GFP-expressing cells at stage 4. Three days after treatment with Blasticidin,
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GFP-expressing clusters remained alive and contracting (supplemental online Movie 6), but
GFP-negative cells were removed (Fig. 2D). GFP-positive clusters were collected with
mechanical methods and treated with 0.25% trypsin-EDTA, and the resultant single cells
were further cultured on 0.1% gelatin coated plates. All contracting cells expressed GFP
(Left panel in Fig. 2E and supplemental online Movie 7) and expressed β-MHC (Fig. 2E,
right panel). Our α-MHC reporter system worked similarly in other hESCs (H1 and H9) and
hiPSCs (BJ1 and E1)(data not shown). Next, we determined the efficiency of CM
differentiation using this reporter system. We counted the number of undifferentiated hPSCs
at stage 1 (Fig. 1A, Day-1) and GFP-positive cells at stage 4 (Fig. 2D) and calculated the
ratio. Fifty to seventy percent of undifferentiated hPSCs were finally committed to CMs at
stage 4. These data indicate that our 2D-directed differentiation system can efficiently
differentiate hPSCs into CMs.
2.4. Three types of AP recorded from hPSC-CMs
To assess the functional activities of hPSC-CMs, we recorded APs from contracting cells.
Stable recordings were obtained from eighteen BJ1-derived and eighteen H1-derived
individual contracting cells. Three major types of APs were observed: nodal-like, atrial-like
and ventricular-like APs (Fig. 3A). Nodal-like APs (Fig. 3A, top) displayed a fast
spontaneous contracting rate, a prominent phase-4 depolarization, a slow upstroke and
relative small amplitude. Ventricular-like APs (Fig. 3A, bottom) were characterized by a
more negative maximum diastolic potential, a fast upstroke and a significant plateau phase
resulting in longer duration and slow contracting rate. Compared to ventricular-like cells,
atrial-like APs (Fig. 3A, middle) did not display a plateau phase during repolarization. In
addition, the maximum diastolic potential of atrial-like APs was less negative than that of
ventricular-like, but more negative than that of nodal-like APs.
Table 1 shows the proportions of contracting BJ1 cells displaying the nodal, atrial and
ventricular-like APs in comparison to the proportions observed from H1-derived contracting
clusters. The proportions of the three cell types were similar between BJ1- and H1-derived
contracting cells, suggesting that this differentiation system can generate three types of CMs
to a similar extent regardless of the original pluripotent cell types. In order to detect whether
the same type of CMs grew together within a given cluster, we recorded APs from three or
more cells within one contracting cluster and measured the AP duration from the peak to
90% repolarization (APD90). As shown in Fig. 3B (bottom) the APD90 values were similar
in cells obtained from the same contracting clusters, but were different from cells obtained
from other clusters. APD90 values of BJ1-derived contracting clusters displayed similar
characteristics to those derived from H1 (Fig. 3B, top). The results suggest that one
predominant CM type was differentiating within a given cluster.
2.5. Gene expression patterns in the 2D-directed CM differentiation system
We analyzed the gene expression patterns at each stage (Fig. 1A, cell populations indicated
by white arrows) by real time RT-PCR (qRT-PCR). Expression levels of mesoderm lineage
markers, such as HAND1, Brachyury, KDR, M-CAD, MESP1 and MESP2, were high at
stage 2 (cell aggregated region) and 3 (clustered region), but were decreased at stage 4 (Fig.
4A). In contrast, cardiac lineage genes began to appear at stage 3 and increased at stage 4 in
both H1 and BJ1 cells (Fig. 4B). Expression of endoderm genes, such as SOX17, FOXA2
and AFP, peaked at stage 3 and decreased at stage 4. TUBB3, an ectoderm and neuronal
gene was highly expressed at stage 2, but decreased at stages 3 and 4 (Fig. 4C) [34]. These
results imply that using FBS in culture at stage 3 induced a decrease in ectodermal gene
expression but increased endodermal gene expression. At stage 4, when contracting clusters
were formed, endodermal gene expression was decreased (Fig. 4C).
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2.6. Spatio-temporal relationship between mesoderm, endoderm and CM
We next examined the interaction between mesoderm, cardiac and endoderm lineage cells
during CM differentiation. At stage 1, OCT4 was strongly expressed (Fig. 5A); however,
mesoderm and endoderm markers were not yet expressed (data not shown). At stage 2,
OCT4 was only expressed in central regions of hPSC colonies (Fig. 5B), but not in the cell
aggregated regions (interfaces of two colonies; yellow line within the boxed region).
Brachyury expression was restricted to the linear aggregated regions and FOXA2-expressing
endodermal cells were observed broadly around aggregated regions (Fig. 5B, right panel).
However, cells expressing CM markers were not yet observed (data not shown). These
results indicate that differentiating cells begin to appear at the periphery of hPSC colonies,
and peripheral cells which are at the interface of original hPSC colonies give rise to
mesoderm lineage.
At stage 3, the linearly aggregated cells formed clearly distinguished round to polygonal
clusters by addition of 10% FBS. At the center of the clusters (Fig. 5C, white circle), cardiac
lineage markers NKX2–5, MEF2C, β-MHC, MLC2v, cTNT, MLC2a, and GATA4 were
expressed. At the periphery of the clusters (Fig. 5C, between the white and yellow circles)
mesoderm lineage markers, HAND1 and Brachyury were expressed (Fig. 5D and 5E). At
the outgrowing region (Fig. 5C, outside of the yellow circle) of the clusters, endodermal
lineage markers, FOXA2, and APF were expressed (Fig. 5F). These results suggest that use
of 10% FBS drives cardiac lineage differentiation from mesodermal cells in the clustered
regions surrounded by endodermal lineage cells at the periphery.
2.7. Contribution of endoderm cells to cardiac lineage commitment
At stage 4, the number of contracting clusters was increased by increasing FBS to 20%, and
these cells showed clear CM characteristics. At stage 4, the boundaries of clusters were
more clearly defined than the clusters at stage 3 (Fig. 6A), expression of CMs was restricted
to the contracting clusters, and mesodermal markers were no longer expressed (Fig. 6A and
6B). Endodermal markers were still present at the periphery of contracting clusters (Fig.
6C). These results suggested that endodermal cells surrounding the clusters could influence
the commitment of mesodermal cells into cardiac lineage. To test this hypothesis, peripheral
cells were removed by trypsin-EDTA treatment at stage 3 and changes at stage 4 were
investigated (Fig. 6D). While the control group induced contracting clusters with decreased
expression of Brachyury at the periphery (Fig. 6D, upper panel), in the enzyme treated
group, Brachyury expression remained strong in the periphery of the clusters and the
number of contracting clusters were reduced more than 10 – fold at stage 4 (Fig. 6D, lower
panel, Fig. 6E). These results indicate that endodermal cells play a crucial role in
differentiation and commitment of mesodermal cells into cardiac lineage.
2. 8. Engraftment of hPSC-derived CMs in the ischemic myocardium
To verify the in vivo behavior of the hPSC-CMs in injured myocardium, we induced
myocardial infarction in nude rats and injected DiI-labeled hPSC-CMs which were enriched
by the monolayer culture. Seven weeks later, we harvested the rat hearts and conducted
histopathologic examination. Masson’s trichrome staining showed islands of patchy
myocardium within circumferential fibrosis suggesting engrafted hPSC-CMs (Supplemental
online Fig. 4A). Confocal microscopic examination revealed clusters of organized DiI-
labeled hPSC-CMs in the infarcted area which expressed cTnT and Connexin 43. These
results suggest that implanted hPSC-CMs were well engrafted, showed mature CM
phenotypes and survived over 7 weeks post transplantation in the infarcted region
(Supplemental online Fig. 4B and 4C). No gross or microscopic tumor was observed in any
gross and microscopic specimens (n = 7).
Moon et al. Page 8
Int J Cardiol. Author manuscript; available in PMC 2014 September 20.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
3. Discussion
In the present study, we developed a novel 2D-directed culture system for differentiating
human PSCs into functional CMs. This newly devised protocol for CM differentiation
produces highly enriched CMs by the simple use of different concentrations of FBS in a
timely fashion based on the morphologic changes concordant with developmental stages.
Three types of CMs (nodal, atrial and ventricular CMs) were generated, with ventricular
type CMs as the major cell type. There were no differences in the yield of CMs between the
hESC- and hiPSC lines that we tried. This differentiation system recapitulates cardiac
development in vivo, and suggests a critical spatiotemporal role of endodermal cells for
differentiation and maturation of CMs from hPSCs.
Various methods have been attempted to differentiate mouse and human PSCs into CMs [6,
14–17]. These include embryoid body (EB)-mediated spontaneous differentiation [15], co-
culturing with endodermal cell line END-2 [6], serum-free cytokine induction [17],
electrical or mechanical stimulation [35], and pharmacological preconditioning [36].
However, most of these studies have used EBs to induce cardiogenic differentiation as an
initial step [24], and these methods can only produce up to 25% differentiated CMs [5, 18].
Our experiments also showed that EB-mediated differentiation was only able to generate
about 15% contracting EBs (supplemental online Fig. 3A and supplemental online Movie 8),
and heterogeneous populations of cells contained in these contracting EBs (supplemental
online Fig. 3B) will require a sorting or purification process before they can be used for cell
therapy or drug screening.
The main goal of this study was to develop a system which can generate CMs from hPSCs
with high yield and purity. We postulated that a monolayer culture system can enhance the
efficiency of CM differentiation by allowing more uniform exposure to growth factors and
oxygen tension. A recent study demonstrated that monolayer culture could achieve an 8.5-
fold increase in cell numbers compared to EB-mediated culture systems [37]. We initiated
culturing hPSCs on growth factor-reduced Matrigel in place of feeder cells to create a more
homogeneous cell population and to eliminate the potential hazards from feeder cells. We
adopted FBS-induced mesodermal and cardiogenic differentiation as it is simple and widely
used for this purpose [34]. Interestingly, in this system we found that morphologic changes
correlate with developmental stages and applying higher FBS concentrations at early cardiac
commitment stages based on morphologic changes can increase the efficiency of CM
differentiation. In this system, 70% of the clusters which appeared in stage 3 (cardiogenic
mesoderm) converted to contracting clusters at stage 4. Through continuous culture, these
cells expressed all representative CM markers such as α, and β-MHC, cTNT, Connexin 43,
MLC2a and MLC2v. When evaluated by a precise α-MHC reporter system, this system
produced CMs at 50 to 70% yield compared to the initially seeded hPSC numbers. When
two-step enzyme treatment was applied to remove non-CMs, the CM yield increased to
95%.
For embryonic cardiogenesis, physical interactions between cells and substances secreted by
different germ layers play vital roles [6, 38]. For instance, BMPs, FGFs and TGF-β secreted
by endoderm lineage help commitment to cardiac lineage in mouse development in vivo
[38] and mouse ESCs differentiation in vitro [39, 40]. During human ESC differentiation
through EBs, endoderm markers SOX17 and FoxA2 were increased concurrently with
mesoderm marker Brachyury, suggesting the interplay between the committed cells for
mutual differentiation [34]. In another hESC study, CM differentiation was achieved by co-
culture with an endoderm lineage cell line (END2) [6]. In addition, endoderm-secreted
factors, such as Activin A and BMP4 are known to increase the expression of cardiac-
specific genes in undifferentiated hESCs [41]. In our study, when mesodermal cells become
Moon et al. Page 9
Int J Cardiol. Author manuscript; available in PMC 2014 September 20.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
aggregated, endodermal cells are surrounding mesodermal cells and appear to interact to
induce mesodermal cells into cardiogenic lineages and maturation of CMs. When the
peripheral endodermal cells were eliminated at stage 3, the number of contracting clusters
was significantly reduced suggesting a crucial role for endoderm in CM maturation. In fact,
this is the first study showing the clear spatiotemporal role of endoderm in the
cardiomyogenic differentiation of hPSCs in vitro.
This 2-dimentional, morphology based, step-wise differentiation system using FBS is a new
system which has many advantages over the previous culture system. First of all, this system
allows generation of highly enriched CMs from hPSCs and thereby can enhance the
therapeutic efficacy and reduce potential side effects. In fact, when these CMs were
implanted into a rat model of myocardial infarction, these cells were engrafted into host
myocardium and showed sustained engraftment without forming tumor. By avoiding the use
of expensive cytokines, this system has additional economic advantages for clinical
application. This system can further function as a useful platform for investigating
developmental biologic events as well as drug evaluation. Particularly, CMs selected by α-
MHC-reporter expression can provide >95% purity and can be highly useful for
pharmacologic testing and genetic studies. As this system recapitulates many of the
molecular events occurring during CM differentiation in vivo based purely on morphologic
observation [42, 43], it can also enable the investigation of epigenetic changes and discovery
of new factors involved in human cardiac differentiation. This novel culture system can be a
highly useful platform for generation of hPSC-derived CMs for regenerative cardiac cell
therapy, pharmacologic testing and human developmental studies.
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Fig. 1.
The differentiation and purification of contracting CMs from hPSCs in a 2D-directed
differentiation system. (A) Overall strategy to differentiate hPSCs into CMs and
representative images in each stage. (B) Contracting clusters at stage 4 before treatment with
0.05% trypsin-EDTA. (C) Cluster morphology after the enzyme treatment. (D) Isolated
contracting clusters after 0.25% trypsin-EDTA treatment. Phase contrast (left panel) and
fluorescent images (center and right panels) showing expression of cTnT and α-MHC. Bar
50 μm. (E) Monolayered cells dissociated from contracting clusters on 0.1% gelatin-coated
plates maintain expression of α-MHC as shown by immunocytochemistry. Bar 100 μm. (F)
Cells dissociated from contracting clusters after 0.25% trypsin-EDTA treatment and plated
on 0.1% gelatin-coated plates still beat and expressed various mature CM proteins. (G)
Percentages of cells expressing CM proteins among monolayered cells after digestion
measured by immunocytochemistry.
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Fig. 2.
Purification of CMs by an α-MHC reporter system. (A) Structure of α-MHC reporter. (B)
Timing of infections of α-MHC reporter containing lentiviruses during CM differentiation.
(C) Contracting clusters infected with viral particles exhibiting α-MHC driven GFP. (D)
Cell clusters after removing non-GFP-expressing cells by treatment with Blasticidin at stage
4. (E) GFP-expressing and Blasticidin resistant CMs were digested by enzyme treatment
(left panel), α-MHC driven GFP-expressing CMs also expressed β-MHC (right panel).
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Fig. 3.
Action potential (AP morphologies of hPSC-CMs. (A) Intracellular recording from 3
different iPS cell-derived CMs demonstrating the 3 major types of AP: nodal-like (top),
atrial-like (middle) and ventricular-like (bottom). (B) CMs within a given cluster
characterized by similar AP morphology. Plot of APD90 measured for each recording in 10
BJ1-derived (top) or H1-derived (bottom) contracting clusters, from which 3 or more cells
were examined.
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Fig. 4.
Gene expression patterns of (A) mesodermal, (B) cardiac lineage and (C) endoderm-
ectodermal markers measured by real-time RT-PCR (n = 3 per group). *P < 0.05; **, P <
0.01; ***, P < 0.001.
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Fig. 5.
Expression patterns of pluripotency and lineage-specific markers in 2D-directed CM
differentiation from undifferentiated hPSCs. (A) At stage 1, Oct4 was strongly expressed in
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hPSCs. (B) At stage 2, Oct4 was expressed in the central region of hPSCs. Mesoderm
marker Brachyury and endoderm marker FoxA2 were broadly expressed in outgrowing cells
of hPSC colonies. (C) Cell clusters appeared and grew at stage 3. (D) Mesoderm lineage
markers were expressed at the peripheral region of the clusters, (E) cardiac lineage markers
were expressed in the center region of the clusters and (F) endoderm lineage markers were
expressed in the outgrowing regions of clusters in stage 3.
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Fig. 6.
Formation of contracting clusters by the presence of endoderm cells. (A, B) Cardiac lineage
markers were exclusively expressed in contracting clusters. (C) Endoderm lineage markers
AFP and FoxA2 were expressed surrounding contracting clusters. (D) Comparison of
expression patterns of mesoderm lineage markers Brachyury and β-MHC according to
existence of endoderm cells. (E) Comparison of the number of contracting clusters between
the control (intact endoderm) and endoderm-depleted groups (n = 7 per group). *P < 0.05.
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Fig. 7.
A working model for CM differentiation in our 2D-direct differentiation system.
Undifferentiated hPSCs were expanded at stage 1. Meso-endoderm lineage cells were
induced from the peripheral region of undifferentiated hPSCs at stage 2. Mesoderm lineage
cells were committed to cardiac lineage cells in aggregated clusters and endoderm cells were
localized to the periphery of aggregated clusters at stage 3. Contracting clusters were further
differentiated into cardiomyocytes at stage 4.
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